AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023

2023-11-17

免疫疗法细胞疗法临床1期AACR会议ASCO会议

- AIC100 ICAM-1 Targeting CAR T Cell Therapy Recognized as Top Global Advance Made by Small Biotechnology Companies - NATICK, Mass. and LONDON, Nov. 17, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards. This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe. AffyImmune topped the list of six finalists deemed to be pioneering new approaches in the treatment of cancer that have shown proof of concept in early clinical trials and have candidates moving forward in the development pathway. "We're thrilled to receive the award, especially in an impressive group of finalists this year; this award is a recognition of the hard work of the AffyImmune team," Chief Operating Officer Matt Britz said. "This is an amazing end to an already successful year, in which we presented early AIC100 safety and clinical data featuring an unprecedented partial response in a patient with anaplastic thyroid cancer. We truly appreciate the confirmation from Scrip and the exposure for our candidate which we believe could greatly improve patient outcomes." About AffyImmune Therapeutics, Inc. AffyImmune is realizing the potential of cancer immunotherapy by extending the anti-cancer activity of CAR T cell therapy to solid tumors. AffyImmune's Tune & Track platform finely tunes the affinity of CAR T cells to reduce toxicity and increase CAR T cell longevity while allowing in vivo monitoring through a proprietary tracking system. The company was founded in 2016 and is enrolling patients in its Phase 1 trial to treat advanced thyroid cancers. Contact Information: Argot Partners Media: Stephanie Jacobson IR: Jonathan Nugent 212-600-1902 AffyImmune@argotpartners.com AffyImmune Therapeutics, Inc. Matt Britz, President & Chief Operating Officer 508-654-3600 mbritz@affyimmune.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构